Skip to main content

Clinical Trials Using Anti-Thymocyte Globulin

Review the clinical trials studying anti-thymocyte globulin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-24 of 24

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Status: Active
Location: 14 locations
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Status: Active
Location: 3 locations
Orca Q Stem Cells for the Treatment of Pediatric Patients with Leukemia
Status: Active
Location: 4 locations
Donor Partial Immune Cell Depletion for the Treatment of Hematologic Malignancies
Status: Active
Location: 2 locations
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Status: Active
Location: 2 locations
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Location: 2 locations
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients with Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Autologous Hematopoietic Stem Cell Transplant for the Treatment of Children and Young Adults with Systemic Sclerosis or Systemic Lupus Erythematosus
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
2 Step ATG with Preparative Chemotherapy and Methotrexate for the Prevention of Acute GVHD for Patients Undergoing Myeloablative Allogeneic Stem Cell Transplant for Hematopoietic Disorders
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Specialized Stem Cell Transplant Product (Hematopoietic Progenitor Blood Cell Graft Cells) for the Treatment of Children, Adolescent and Young Adult Patients with Hematologic Cancers
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
T Cell Receptor Alpha/Beta Depletion Peripheral Blood Stem Cell Transplantation for the Prevention of Graft Versus Host Disease in Children and Adults with Hematological Malignancies
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Modified Donor Peripheral Blood Stem Cells in Combination with Zoledronic Acid for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory Solid Tumors
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Modified Memory-Like NK Cells and TCRαβ T-cell Depleted Half-Matched Related Donor Transplant for the Treatment of High-Risk Acute Myeloid Leukemia (ABCD NK trial)
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients with Relapsed Hematologic Cancers Undergoing a Second or above Donor Stem Cell Transplant
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Donor Blood Stem Cells (Ex Vivo TCR Alpha/Beta and CD19-Depleted Stem Cells) for the Prevention of Graft-versus-Host Disease in Pediatric Patients with Blood Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
TCR Alpha/Beta-Depleted Progenitor Cells with CD45RA-Depleted Donor Lymphocyte Infusion and Selected Use of Blinatumomab in Children and Young Adults with Blood Cancers at High Risk for Relapse
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Status: Active
Location: See ClinicalTrials.gov
TCRalpha/beta and CD19+ depleted Hematopoietic Stem Cell Transplant from Closely Matched Unrelated Donors or Haploidentical Related donors for Blood Disorders in Children and Young Adults
Status: Approved
Location: 2 locations
Immune Suppression Treatment for People With Sickle Cell Disease or Beta-Thalassemia Who are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Status: Active
Location: 7 locations